In summary, a combination of these three HRM optimized probes would differentiate tumors from non-tumors (using GPM6B probe and MAGEA12 in combination with GPM6B) and HCC with PVTT from non-PVTT HCC (using FCRL1 probe). Here, FCRL1 is linked to hepatocellular carcinoma.